Aldosterone Administration to Mice Stimulates Macrophage NADPH Oxidase and Increases Atherosclerosis Development: A Possible Role for Angiotensin-Converting Enzyme and the Receptors for Angiotensin II and Aldosterone

Circulation

Volumn 109, Issue 18, 2004, Pages 2213-2220

  Keidar, Shlomo ^a   Kaplan, Marielle ^a   Pavlotzky, Elsa ^a   Coleman, Raymond ^a   Hayek, Tony ^a   Hamoud, Shadi ^a   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Aldosterone; Angiotensin; Angiotensin converting enzyme; Atherosclerosis; Macrophages

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; LOSARTAN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PROTEIN P47; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 3; IN VITRO STUDY; LIPID OXIDATION; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELL LINE; ENZYME INDUCTION; HORMONE ANTAGONISTS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LOSARTAN; MACROPHAGES, PERITONEAL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RAMIPRIL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SPIRONOLACTONE; SUPEROXIDES;

EID: 2442490850     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000127949.05756.9D     Document Type: Article

References (34)

1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis, basic mechanisms: oxidation, inflammation and genetics. Circulation. 1995;91: 2488-2496.
2. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
3. Parthasarathy S, Santanam N. Mechanisms of oxidation, antioxidants and atherosclerosis. Curr Opin Lipidol. 1994;5:371-375.
4. Aviram M. Review of human studies on oxidative damage and anti-oxidant protection related to cardiovascular diseases. Free Radic Res. 2000;33:S85-S97.
5. Steinberg D. LDL oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
6. Levy R, Rotrosen D, Nagauker O, et al. Induction of the respiratory burst in HL-60 cells: correlation of function and protein expression. J Immunol. 1990;145:2595-2601.
7. Groemping Y, Lapouge K, Smerdon SJ, et al. Molecular basis of phosphorylation-induced activation of the NADPH-oxidase. Cell. 2003:113: 343-355.
8. Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
9. Rocha R, Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
10. Sun Y, Ratajska A, Zhou G, et al. Angiotensin-converting-enzyme and myocardial fibrosis in the rat receiving angiotensin-II or aldosterone. J Lab Clin Med. 1993;122:395-403.
11. Xiao F, Puddefoot JR, Vinson GP. Aldosterone mediates angiotensin-II stimulated rat vascular smooth muscle cell proliferation. J Endocrinol. 2000;165:533-536.
12. Farquharson CA, Struthers AD. Spironolactone increases NO bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin-I/angiotensin-II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
13. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139.
14. Wang J, Yu L, Solenberg PJ, et al. Aldosterone stimulates ACE expression and activity in rat neonatal cardiac myocytes. J Card Fail. 2002;8:167-174.
15. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
16. Rajagopafan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105: 2212-2216.
17. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002; 40:504-510.
18. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress and atherosclerosis in apolipoprotein-E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955-963.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;2:341: 709-717.
20. 0 mice. Biochem Biophys Res Commun. 1994;201: 1567-1574.
21. Holmquist B, Bunn P, Riordan KA. Spectrophotometric assay for ACE. Anal Biochem. 1979;95:540-544.
22. 0 mice and from human carotid artery contain lipid peroxides and oxysterols. Biochem Biophys Res Commun. 2000;269:775-780.
23. Johnston RB, Keele BB, Mirsa HP, et al. The role of superoxide anion generation in phagocytic bactericidal activity. J Clin Invest. 1975; 55:1357.
24. Li Y, Zhu H, Kuppusamy P, et al. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998;173:2015-2023.
25. Yanagitani Y, Rakugi H, Okamura A, et al. Angiotensin-II type-1 receptor-mediated peroxide production in human macrophages. Hypertension. 1999;33:335-339.
26. Aviram M, Vaya J. Markers for LDL oxidation. Methods Enzymol. 2001;335:244-256.
27. Nunoi H, Rotrosen D, Gallin JI, et al. Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science. 1988;242:1298-1301.
28. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT-1 receptor signaling reduced tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun. 2002;294:441-447.
29. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002; 144:S2-S7.
30. Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003;87:441-457.
31. Laursen JB, Rajagopalan S, Galis Z. Role of superoxide in angiotensin-II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
32. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 1309-1321.
33. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med. 1981;141:1589-1593.
34. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108:1831-1838.